Award
National Institute of Allergy and Infectious Diseases 1R01AI198553-01
Efficacy of targeting GAPM3 to block acute and chronic Toxoplasma gondii infections
Recipient
National Institute of Allergy and Infectious Diseases (NIAID), part of NIH
Award Amount
$463,290.00
Ceiling
$463,290.00
Awarded
June 24, 2026
Identifier
1R01AI198553-01
NIH/NIAID awarded approximately $463,290 for research on targeting GAPM3 to treat Toxoplasma gondii infections, focusing on drug development and translational research.
Description
This project aims to evaluate the efficacy of targeting the membrane protein GAPM3 in Toxoplasma gondii to treat acute and chronic infections. The award amount is approximately $463,290, with a focus on drug development and translational research. The project is funded by the NIH/NIAID and is part of the PA-25-301 funding opportunity. The project duration is from June 24, 2026, to May 31, 2031.